

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Gabture 400mg Hard Capsules

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard capsule contains 400mg Gabapentin

Each hard capsule contains 67.333mg lactose monohydrate

For a full list of excipients see section 6.1

3 PHARMACEUTICAL FORM

Capsule, hard (Capsules)

Size ‘0’ orange/orange hard gelatine capsule marked ‘MG 400’

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Epilepsy:

Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalisation in adults and children aged 6 years and above (see section 5.1).

Gabapentin is indicated as monotherapy in the treatment of partial seizures with and without secondary generalisation in adults and adolescents aged 12 years and above.

Treatment of peripheral neuropathic pain:

Gabapentin is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults.

4.2 Posology and method of administration

For oral use.

Gabapentin can be given with or without food and should be swallowed whole with sufficient fluid intake (e. g. glass of water)

For all indications a titration scheme of the initiation of therapy is described in Table 1, which is recommended in adults and adolescents aged 12 years and above. Dosing instructions for children under 12 years of age are provided under separate sub-heading later in this section.

Table 1

Dosing chart – initial titration		
Day 1	Day 2	Day 3
300mg once a day	300mg two times a day	300mg three times a day

Discontinuation of Gabapentin

In accordance with current clinical practice, if Gabapentin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication.

Epilepsy

Epilepsy typically requires long-term therapy. Dosage is determined by the treating physician according to individual tolerance and efficacy.

Adults and adolescents

In clinical trials the effective dose of Gabapentin is 900-3600 mg/day. Therapy may be initiated by titrating the dose as described in Table 1 or by administering 300 mg three times a day (TID) on Day 1. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300mg/day increments every 2-3 days up to a maximum dose 3600 mg/day. Slower titration of Gabapentin dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks. Dosages up to 4800 mg/day have been well tolerated in long-term open-label clinical studies. The total daily dose should be divided in three single doses, the maximum time interval between the doses should not exceed 12 hours to prevent breakthrough convulsions.

Children aged 6 years and above

The starting dose should range from 10 to 15 mg/kg/day and the effective dose is reached by upward titration over a period of approximately three days. The effective dose of Gabapentin in children aged 6 years and older is 25 to 35 mg/kg/day. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The total daily dose should be divided in three single doses, the maximum time interval between doses should not exceed 12 hours.

It is not necessary to monitor Gabapentin plasma concentrations to optimise gabapentin therapy. Further, gabapentin may be used in combination with other antiepileptic medicinal products without concern for alteration of the plasma concentrations of gabapentin or serum concentrations of other antiepileptic medicinal products.

Peripheral Neuropathic Pain

Adults

The therapy may be initiated by titration the dose as described in Table 1. Alternatively, the starting dose is 900 mg/day given as three equally divided doses. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration if gabapentin dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks.

In the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than 5 months. If a patient requires dosing longer than 5 months of the treatment of peripheral neuropathic pain, the treating physician should assess the patient's clinical status and determine the need for additional therapy.

Instruction for all areas of indication

In patients with poor general health, i.e., low body weight, after organ transplant etc., the dose should be titrated more slowly, either by using smaller dosage strengths or longer intervals between dosage increases.

Use in elderly patients (over 65 years of age)

Elderly patients may need dosage adjustment due to decline of renal function with age (see Table 2). Somnolence, peripheral oedema and asthenia may be more frequent in elderly patients.

Use in patients with renal impairment.

Dosage adjustment is recommended in patients with compromised renal function as described in Table 2 and/or those undergoing haemodialysis. Gabapentin 100mg capsules can be used to follow dosing recommendations for patients with renal insufficiency.

Table 2

Dosage of gabapentin in adults based on renal function	
Creatinine Clearance (mL/min)	Total Daily Dose ^a (mg/day)
≥ 80	900-3600
50-79	600-1800
30-49	300-900
15-29	150 ^b -600
< 15 ^c	150 ^b -300

^a Total daily dose should be administered as three divided doses. Reduced dosages are for patients with renal impairment (creatinine clearance < 79 ml/min).

^b To be administered as 300mg every other day.

^c For patients with creatinine clearance < 15 ml/min, the daily dose should be reduced in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 ml/min should receive one-half the daily dose that patients with creatinine clearance of 15 ml/min receive).

Use in patients undergoing haemodialysis

For anuric patients undergoing haemodialysis who have never received gabapentin, a loading dose of 300 mg to 400 mg, then 200 mg to 300 mg of gabapentin following each 4 hours of haemodialysis, is recommended. On dialysis free days, there should be no treatment with gabapentin.

For renally impaired patients undergoing haemodialysis, the maintenance dose of gabapentin should be based on the dosing recommendations found in Table 2. In addition to the maintenance dose, an additional 200 to 300 mg dose following each 4-hour haemodialysis treatment is recommended.

4.3 Contraindications

Gabapentin is contraindicated in patients who have shown hypersensitivity to any of the constituents.

4.4 Special warnings and precautions for use

If a patient develops acute pancreatitis under treatment with gabapentin, discontinuation of gabapentin should be considered (see section 4.8).

Although there is no evidence of rebound seizure with gabapentin, abrupt withdrawal of anticonvulsant agents in epileptic patients may precipitate status epilepticus (see section 4.2).

As with other antiepileptic medicinal products, some patients may experience an increase in seizure frequency or the onset of new types of seizures with gabapentin.

As with other anti-epileptics, attempts to withdraw concomitant anti-epileptics in treatment refractive patients on more than one anti-epileptic, in order to reach gabapentin monotherapy have a low success rate.

Gabapentin is not considered effective against primary generalised seizures such as absences and may aggravate these seizures in some patients. Therefore, gabapentin should be used with caution in patients with mixed seizures including absences.

No systematic studies in patients 65 years or older have been concluded with gabapentin. In one double blind study in

patients with neuropathic pain, somnolence, peripheral oedema and asthenia occurred in a somewhat higher percentage in patients aged 65 years or above, than in younger patients. Apart from these findings, clinical investigations in this age group do not indicate an adverse event profile different from that observed in younger patients.

The effects of long-term (greater than 36 weeks) gabapentin therapy on learning, intelligence, and development in children and adolescents have not been adequately studied. The benefits of prolonged therapy must therefore be weighed against the potential risks of such therapy.

Laboratory tests

False positive readings may be obtained in the semi-quantitative determination of total urine protein by dipstick tests. It is therefore recommended to verify such a positive dipstick test result by methods based on a different analytical principle such as the Biuret method, turbidimetric or dye-binding methods, or to use these alternative methods from beginning.

Gabture capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Gabture capsules.

4.5 Interaction with other medicinal products and other forms of interaction

In a study involving healthy volunteers (N=12), when a 60 mg controlled-release Morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule, mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine. Therefore, patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of gabapentin or morphine should be reduced appropriately.

No interaction was observed between gabapentin and phenytoin, valproic acid, carbamazepine or Phenobarbital. Steady-state pharmacokinetics of gabapentin are similar for healthy subjects and patients with epilepsy receiving antiepileptic agents.

Co-administration of gabapentin with oral contraceptives containing norethindrone and/or ethinyl oestradiol presents no influence on the steady-state pharmacokinetic of either component.

Co-administration of antacids containing aluminium and magnesium reduces the bioavailability of gabapentin up to 24%. It is recommended that gabapentin be taken at the earliest two hours of antacid administration.

Renal excretion of gabapentin is not altered by probenecid.

A slight decrease in renal excretion of gabapentin, that is observed when co-administered with cimetidine, is not expected to be of clinical importance.

4.6 Fertility, pregnancy and lactation

Risk related to epilepsy and antiepileptic medicinal products in general

The risk of birth defects is increased by factor of 2-3 in the offspring of mothers treated with an antiepileptic medicinal product. Most frequently reported are cleft lip, cardiovascular malformations and neural tube defects. Multiple antiepileptic drug therapy may be associated with a higher risk of congenital malformations than monotherapy, therefore it is important that monotherapy is practised whenever possible. Specialist advice should be given to women who are likely to become pregnant or who are of childbearing potential and the need for antiepileptic treatment should be reviewed when a woman is planning to become pregnant. No sudden discontinuation of antiepileptic therapy should be undertaken as this may lead to breakthrough seizures, which could have serious consequences of both mother and child.

Developmental delay in children of mothers with epilepsy has been observed rarely. It is not possible to differentiate if the developmental delay is caused by genetic, social factors, maternal epilepsy or the antiepileptic therapy.

Risk related to gabapentin

There are no adequate data from the use of gabapentin in pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Gabapentin should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.

No definite conclusion can be made as to whether gabapentin is associated with an increased risk of congenital malformations when taken during pregnancy, because of epilepsy itself and presence of concomitant antiepileptic medicinal products during each reported pregnancy.

Gabapentin is excreted in human milk. Because the effect of the breast-fed infant is unknown, caution should be exercised when gabapentin is administered to a breast-feeding mother. Gabapentin should be used in breast-feeding mothers only if the benefits clearly outweigh the risks.

4.7 Effects on ability to drive and use machines

Gabapentin may have minor or moderate influence on the ability to drive and use machines, Gabapentin acts on the central nervous system and may cause drowsiness, dizziness, or other related symptoms. Even, if they were only mild or moderate degree, these undesirable effects could be potentially dangerous to patients driving or using machinery. This is especially true at the beginning of the treatment and after increase in dose.

4.8 Undesirable effects

The adverse reactions observed during clinical studies conducted in epilepsy (adjunctive and monotherapy) and neuropathic pain have been provided in a single list below by class and frequency very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1000$ to $< 1/100$); rare ($\geq 1/10000$ to $< 1/1000$); very rare ($< 1/10000$). Where an adverse reaction was seen at different frequencies in clinical studies, it was assigned to the highest frequency reported.

Additional reactions reported from post-marketing experience are included as frequency 'Not known' (cannot be estimated from the available data) in italics in the list below.

With each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Infections and infestations

Very common: viral infection

Common: pneumonia, respiratory infection, urinary tract infection, infection, otitis media

Blood and the lymphatic system disorders

Common: leucopenia

Not known: *thrombocytopenia*

Immune system disorders

Uncommon: allergic reactions (e.g. urticaria)

Metabolism and nutritional disorders

Common: anorexia, increased appetite

Psychiatric disorders

Common: hostility, confusion and emotional lability, depression, anxiety, nervousness, thinking abnormal

Not known: *hallucinations*

Nervous system disorders

Very common: somnolence, dizziness, ataxia

Common: convulsions, hyperkinesia, dysarthria, amnesia, tremor, insomnia, headache, sensations such as paresthesia, hypoesthesia, coordination abnormal, nystagmus, increased, decreased or absent reflexes

Uncommon: hypokinesia

Not known: *other movement disorders (e.g. choreoathetosis, dyskinesia, dystonia)*

Eye disorders:

Common: visual disturbances such as amblyopia, diplopia

Ear and labyrinth disorders

Common: vertigo

Not known: *tinnitus*

Cardiac disorders

Uncommon: palpitations

Respiratory, thoracic and mediastinal disorders

Common: dyspnoea, bronchitis, pharyngitis, cough, rhinitis

Gastrointestinal disorders

Common: vomiting, nausea, dental abnormalities, gingivitis, diarrhoea, abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence

Not known: *pancreatitis*

Hepatobiliary disorders

Not known: *hepatitis, jaundice*

Skin and subcutaneous tissue disorders

Common: facial oedema, purpura most often described as bruises resulting from physical trauma, rash, pruritus, acne

Not known: *Stevens-Johnson syndrome, angioedema, erythema multiforme alopecia*

Musculoskeletal, connective tissue and bone disorders

Common: Arthralgia, myalgia, back pain, twitching

Not known: *myoclonus*

Renal and urinary disorder

Not known: *acute renal failure, incontinence*

Reproductive system and breast disorders

Common: impotence

Not known: *breast hyperthrophy, gynaecomastia*

General disorders and administration site conditions

Very common: fatigue, fever

Common: peripheral oedema, abdominal gait, asthenia, pain, malaise, flu symptoms

Uncommon: generalised oedema

Not known: *withdrawal reactions (mostly anxiety, insomnia, nausea, pains, sweating), chest pain. Sudden unexplained deaths have been reported where a casual relationship to treatment with gabapentin has not been established.*

Investigations

Common: WBC (white blood cell count) decreased, weight gain

Uncommon: elevated liver function tests SGOT (AST), SGPT (ALT) and bilirubin

Not known: *blood glucose fluctuations in patients with diabetes*

Injury and poisoning

Common: accidental injury, fracture, abrasion

Under treatment with gabapentin cases of acute pancreatitis were reported. Sausality with gabapentin is unclear (see section 4.4.)

In patients on haemodialysis due to end-stage renal failure, myopathy with elevated creatine kinase levels has been reported.

Respiratory tract infections, otitis media, convulsions and bronchitis were reported only in clinical studies in children. Additionally, in clinical studies in children, aggressive behaviour and hyperkinesias were reported commonly.

4.9 Overdose

Acute, life-threatening toxicity has not been observed with gabapentin overdoses of up to 49g. Symptoms of the overdoses included dizziness, double vision, slurred speech, drowsiness, lethargy and mild diarrhoea.

All patients recovered fully with supportive care. Reduced absorption of gabapentin at higher doses may limit drug absorption at the time of overdosing and, hence, minimise toxicity from overdoses.

Overdoses of gabapentin, particularly in combination with other CNS depressant medications may result in coma.

Although gabapentin can be removed by haemodialysis, based on prior experience it is not usually required. However, in patients with renal impairment, haemodialysis may be indicated.

An oral lethal dose of gabapentin was not identified in mice and rats given doses as high as 8000 mg/kg. Signs of acute toxicity in animals included ataxia, laboured breathing, ptosis, hypoactivity, or excitation.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other antiepileptics. ATC code: N03AX12

The precise mechanism of action of gabapentin is not known.

Gabapentin is structurally related to neurotransmitter GABA (gamma-amino butyric acid) but its mechanism of action is different from that of several other active substances that interact with GABA synapses including valproate, barbiturates, benzodiazepines, GABA transaminase inhibitors, GABA uptake inhibitors and GABA prodrugs. *In vitro* studies with radiolabeled gabapentin have characterized a novel peptide binding site in rat brain tissues including neocortex and hippocampus that may relate to anticonvulsant and analgesic activity of gabapentin and its structural derivatives. The binding site for gabapentin has been identified as the α_2 -delta subunit of voltage-gated calcium channels.

Gabapentin at relevant clinical concentrations does not bind to other common drug or neurotransmitter receptors of the brain including GABA_A, GABA_B, benzodiazepine, glutamate, glycine or N-methyl-d-aspartate receptors.

Gabapentin does not interact with sodium channels *in vitro* and so differs from phenytoin and carbamazepine. Gabapentin partially reduces responses to the glutamate agonist N-methyl-d-aspartate (NMDA) in some test systems *in vitro*, but only at concentrations greater than 100 μ M, which are not achieved *in vitro*. Gabapentin slightly reduces the release of monoamine neurotransmitters *in vitro*. Gabapentin administration to rats increases GABA turnover in several brain regions in a manner similar to valproate sodium, although in different regions of brain. The relevance of these various actions of gabapentin to anticonvulsant effects remains to be established. In animals, gabapentin readily enters the brain and prevents seizures from maximal electroshock, from chemical convulsants including inhibitors of GABA synthesis, and in genetic models of seizures.

A clinical trial of adjunctive treatment of partial seizures in paediatric subjects ranging in age from 3 to 12 years, showed a numerical but not statistically significant difference in the 50% responder rate in favour of the gabapentin group compared to placebo. Additional post-hoc analyses of the responder rates by age did not reveal a statistically significant effect of age, either as a continuous or dichotomous variable (age groups 3-5 and 6-12 years).

The data from this additional post-hoc analysis are summarised in the table below:

Response (50% improved) by treatment and age MITT* population			
Age category	Placebo	Gabapentin	P-value
< 6 years old	4/21 (19.0%)	4/17 (23.5%)	0.7362
6 to 12 years old	17/99 (17.2%)	20/96 (20.8%)	0.5144

* The modified intent to treat population was defined as all patients randomised to study medication who also had evaluable seizure diaries available for 28 days during both the baseline and double-blind phases.

5.2 Pharmacokinetic properties

Absorption

Following oral administration, peak plasma gabapentin concentrations are observed within 2 to 3 hours. Gabapentin bioavailability (fraction of dose absorbed) tends to decrease with increasing dose. Absolute bioavailability of a 300 mg capsule is approximately 60%. Food, including high-fat diet, has no clinically significant effect on gabapentin pharmacokinetics.

Gabapentin pharmacokinetics are not affected by repeated administration. Although plasma gabapentin concentrations were generally between 2 µg/ml and 20 µg/ml in clinical studies, such concentrations were not predictive of safety or efficacy. Pharmacokinetic parameters are given in Table 3.

Table 3

Summary of gabapentin mean (%CV) steady-state pharmacokinetic parameters following every eight hours administration

Pharmacokinetic parameter	300mg (N=7)		400mg (N=14)		800mg (N=14)	
	Mean	%CV	Mean	%CV	Mean	%CV
C _{max} (µg/ml)	4.02	(24)	5.74	(38)	8.71	(29)
t _{max} (hr)	2.7	(18)	2.1	(54)	1.6	(76)
T½ (hr)	5.2	(12)	10.8	(89)	10.6	(41)
AUC (0-8) (µg*hr/ml)	24.8	(24)	34.5	(34)	51.4	(27)
Ar% (%)	NA	NA	47.2	(52)	34.4	(37)

C_{max} - Maximum steady state plasma concentration

t_{max} - Time for C_{max}

T½ - Elimination half-life

AUC (0-8) - Steady state area under plasma concentration-time curve from time 0 to 8 hours postdose

Ae% - Percent of dose excreted unchanged into the urine from time 0 to 8 hours postdose

NA - Not available

Distribution

Gabapentin is not bound to plasma proteins and has a volume of distribution equal to 57.7 litres. In patients with epilepsy, gabapentin concentrations in cerebrospinal fluid (CSF) are approximately 20% of corresponding steady state through plasma concentrations. Gabapentin is present in the breast milk of breast-feeding women.

Metabolism

Gabapentin is not metabolized in humans and does not induce hepatic mixed function oxidase enzymes responsible for drug metabolism.

Elimination

Gabapentin is eliminated unchanged solely by renal excretion. The elimination half-life of gabapentin is independent of dose and averages 5 to 7 hours.

In elderly patients, and in patients with impaired renal function, gabapentin plasma clearance is reduced. Gabapentin elimination-rate constant, plasma clearance, and renal clearance are directly proportional to creatinine clearance.

Gabapentin is removed from plasma by haemodialysis. Dosage adjustment in patients with compromised renal function or undergoing haemodialysis is recommended (see section 4.2)

Gabapentin pharmacokinetics in children was determined in 50 healthy subjects between the ages of 1 month and 12 years. In general, plasma gabapentin concentrations in children > 5 years of age are similar to those in adults when dosed on an mg/kg basis.

Linearity/ Non-linearity

Gabapentin bioavailability (fraction of dose absorbed) decreases with increasing dose which imparts non-linearity to pharmacokinetic parameters which include the bioavailability parameter (F) e.g. Ae%, CL/F, Vd/F. Elimination pharmacokinetics (pharmacokinetic parameters which do not include F such as CLr and T_{1/2}), are best decreased by linear pharmacokinetics. Steady state plasma gabapentin concentrations are predictable from single-dose data.

5.3 Preclinical safety data

Carcinogenesis

Gabapentin was given in the diet of mice at 200, 600 and 2000 mg/kg/day and to rats at 250, 1000 and 2000 mg/kg/day for two years. A statistically significant increase in the incidence of pancreatic acinar cell tumours was found only in male rats at the highest dose. Peak plasma drug concentrations and areas under the concentration time curve in rats at 2000 mg/kg is 10 times higher than therapeutic dose of 3600 mg/day. The pancreatic acinar cell tumours in male rats were low grade malignancies, did not affect survival, did not metastasise or invade surrounding tissue, and were similar to those seen in concurrent controls. The relevance of these pancreatic acinar cell tumours in male rats to carcinogenic risk in humans is unclear.

Mutagenesis

Gabapentin demonstrated no genotoxic potential. It was not mutagenic *in vitro* in standard assays using bacterial or mammal cells. Gabapentin did not include structural chromosome aberrations in mammalian cells *in vitro* or *in vivo*, and did not include micronucleous formation in the bone marrow of hamsters.

Impairment of fertility

No adverse effects on fertility or reproduction were observed in rats at doses up to 2000 mg/kg (approximately five times the maximum daily dose on an mg/m² of body surface are basis).

Teratogenesis

Gabapentin did not increase the incidence of malformations, compared to controls in the offspring of mice, rats, or rabbits at doses up to 50, 30 and 25 times respectively, the daily human dose of 3500 mg, (four, five or eight times, respectively, the human daily dose on an mg/m² of body surface are basis).

Gabapentin included delayed ossification in the skull, vertebrae, forelimbs, and hind limbs in rodents, indicative of foetal growth retardation. These effects occurred when pregnant mice received oral doses of 1000 or 3000 mg/kg/day during organogenesis and in rats given 500, 1000 or 2000 mg/kg prior to and during mating and through gestation.

These doses are approximately 1 to 5 times the human dose of 3600 mg on an mg/m^2 basis.

No effects were observed in pregnant mice given 400mg/kg/day (approximately $\frac{1}{2}$ of the daily human dose on an mg/m^2 basis).

An increased incidence of hydroureter and/or hydronephrosis was observed in rats given 2000 mg/kg/day in a fertility and general reproduction study, 1500 mg/kg/day in a teratology study, and 500, 1000 and 2000 mg/kg/day in perinatal and postnatal study. The significance of these findings is unknown, but they have been associated with delayed development. These doses are also approximately 1 to 5 times the human dose of 3600 mg on an mg/m^2 basis.

In a teratology study in rabbits, an increased incidence of post-implantation fetal loss, occurred in doses given 60, 300 and 1500 mg/kg/day during organogenesis. These doses are approximately $\frac{1}{4}$ to 8 times the daily human dose of 3600 mg on an mg/m^2 basis.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate

Maize starch

Talc

Capsule shell:

Gelatin

Titanium dioxide (E171)

Yellow iron oxide (E172)

Red iron oxide (E172)

Printing ink: (Opacode Black S-I-8015 HV)

Shellac (E904)

Vegetable carbon (E153)

Industrial Methylated Spirit

Antifoam DC 1510

Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

18 months.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

The capsules are packed in 10's blisters constituted from 250µm PVC and 25µm aluminium foil. Pack size of 100 capsules.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements

7 MARKETING AUTHORISATION HOLDER

Milpharm Limited
Ares, Odyssey Business Park
West End Road
South Ruislip, HA4 6QD
United Kingdom

8 MARKETING AUTHORISATION NUMBER

PA 1050/1/3

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18 November 2003

Date of last renewal: 18 November 2008

10 DATE OF REVISION OF THE TEXT

November 2012